We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.68 | 0.70% | 98.18 | 443 | 10:44:07 |
From May 2022 to May 2024
By Joshua Kirby
Novartis AG said Monday that an integrated trial of denosumab, a proposed biosimilar developed by its subsidiary Sandoz, generated positive results.
Denosumab is indicated for the treatment of various conditions including osteoporosis.
An integrated Phase 1-3 study of the biosimilar met its primary endpoints of matching reference medicines and contributing to demonstration of similarity, the Swiss drugmaker said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
September 19, 2022 01:51 ET (05:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
